ES2295924T3 - Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. - Google Patents

Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. Download PDF

Info

Publication number: ES2295924T3
Authority: ES; Spain
Prior art keywords: formula; baselineskip; compound; methyl; azabicyclo
Prior art date: 2003-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04769496T

Other languages

English (en)

Spanish (es)

Inventor

Paul Anthony Stupple

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PFIZER

Pfizer Inc

Original Assignee

PFIZER

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-03

Filing date

2004-09-28

Publication date

2008-04-16

2003-10-03 Priority claimed from GBGB0323236.0A external-priority patent/GB0323236D0/en

2003-10-27 Priority claimed from GB0325020A external-priority patent/GB0325020D0/en

2004-08-19 Priority claimed from GB0418566A external-priority patent/GB0418566D0/en

2004-09-28 Application filed by PFIZER, Pfizer Inc filed Critical PFIZER

2008-04-16 Application granted granted Critical

2008-04-16 Publication of ES2295924T3 publication Critical patent/ES2295924T3/es

2024-09-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)

ES04769496T 2003-10-03 2004-09-28 Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. Expired - Lifetime ES2295924T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GBGB0323236.0A GB0323236D0 (en)	2003-10-03	2003-10-03	Chemical compounds
GB0323236		2003-10-03
GB0325020		2003-10-27
GB0325020A GB0325020D0 (en)	2003-10-27	2003-10-27	Chemical compounds
GB0418566		2004-08-19
GB0418566A GB0418566D0 (en)	2004-08-19	2004-08-19	Tropane derivatives

Publications (1)

Publication Number	Publication Date
ES2295924T3 true ES2295924T3 (es)	2008-04-16

Family

ID=34426592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES04769496T Expired - Lifetime ES2295924T3 (es)	2003-10-03	2004-09-28	Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.

Country Status (35)

Country	Link
US (2)	US7309790B2 (pl)
EP (1)	EP1682545B1 (pl)
JP (1)	JP4874107B2 (pl)
KR (1)	KR100777885B1 (pl)
AP (1)	AP2174A (pl)
AR (1)	AR045856A1 (pl)
AT (1)	ATE380813T1 (pl)
AU (1)	AU2004278158B2 (pl)
BR (1)	BRPI0414862A (pl)
CA (1)	CA2540834C (pl)
CY (1)	CY1107281T1 (pl)
DE (1)	DE602004010708T2 (pl)
DK (1)	DK1682545T3 (pl)
EA (1)	EA009941B1 (pl)
EC (1)	ECSP066475A (pl)
ES (1)	ES2295924T3 (pl)
GE (1)	GEP20084417B (pl)
HN (1)	HN2004000383A (pl)
HR (1)	HRP20080052T3 (pl)
IL (1)	IL174208A0 (pl)
MA (1)	MA28080A1 (pl)
MX (1)	MXPA06003749A (pl)
MY (1)	MY137609A (pl)
NO (1)	NO20061978L (pl)
NZ (1)	NZ545837A (pl)
OA (1)	OA13266A (pl)
PA (1)	PA8614301A1 (pl)
PE (1)	PE20050961A1 (pl)
PL (1)	PL1682545T3 (pl)
PT (1)	PT1682545E (pl)
RS (1)	RS20060198A (pl)
SI (1)	SI1682545T1 (pl)
TW (1)	TWI280244B (pl)
UY (1)	UY28546A1 (pl)
WO (1)	WO2005033107A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (es)	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
CN102358738A (zh)	2003-07-30	2012-02-22	里格尔药品股份有限公司	2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP1904457B1 (en)	2005-06-08	2017-09-06	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
CL2007000945A1 (es) *	2006-04-05	2008-01-25	Schering Corp	Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
WO2008030853A2 (en) *	2006-09-06	2008-03-13	Incyte Corporation	Combination therapy for human immunodeficiency virus infection
ATE497496T1 (de)	2006-10-19	2011-02-15	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
WO2008085302A1 (en) *	2006-12-20	2008-07-17	Merck & Co., Inc.	Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
AR065802A1 (es) *	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
RS51346B (sr) *	2007-10-25	2011-02-28	Exelixis, Inc.	Jedinjenja tropana
HUE030912T2 (en)	2008-02-15	2017-06-28	Rigel Pharmaceuticals Inc	Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
MX2010011463A (es)	2008-04-16	2011-06-03	Portola Pharm Inc	2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
JP2011518219A (ja)	2008-04-22	2011-06-23	ポートラファーマシューティカルズ，インコーポレイテッド	タンパク質キナーゼの阻害剤
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
BR112012003263A2 (pt)	2009-08-14	2015-09-22	Opko Health Inc	formulações intravenosas de antagonistas de neuroquinina-1
MX2012011415A (es)	2010-04-02	2013-02-26	Phivco 1 Llc	Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
EP2635557A2 (en)	2010-11-01	2013-09-11	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
WO2013024022A1 (en)	2011-08-12	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
SG11201402570QA (en)	2011-11-23	2014-06-27	Portola Pharm Inc	Pyrazine kinase inhibitors
US9676756B2 (en)	2012-10-08	2017-06-13	Portola Pharmaceuticals, Inc.	Substituted pyrimidinyl kinase inhibitors
JP6224256B2 (ja) *	2013-09-25	2017-11-01	マリンクロッドエルエルシー	放射ヨウ素標識された３−フルオロプロピル−ＮＯＲ−β−ＣＩＴの調製
GB201321748D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
US11629196B2 (en)	2020-04-27	2023-04-18	Incelldx, Inc.	Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2023192360A1 (en) *	2022-03-31	2023-10-05	Incelldx, Inc.	Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same
WO2023192361A1 (en) *	2022-03-31	2023-10-05	Incelldx, Inc.	Methods of treating a subject for fibromyalgia and compositions for use in the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EE03877B1 (et)	1994-04-19	2002-10-15	Neurosearch A/S	Tropaan-2-aldoksiimi derivaadid neurotransmitteritagasihaarde inhibiitoritena
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
BR9707636A (pt)	1996-02-22	1999-07-27	Neurosearch As	Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
PE20001420A1 (es) *	1998-12-23	2000-12-18	Pfizer	Moduladores de ccr5
HRP20020938B1 (en) *	2000-05-26	2011-05-31	Pfizer Inc.	Tropane derivatives useful in therapy
RS51550B (sr) *	2002-04-08	2011-06-30	Pfizer Inc.	Derivati tropana kao modulatori ccr5
US6855724B2 (en) *	2002-04-08	2005-02-15	Agouron Pharmaceuticals, Inc.	Tropane derivatives useful in therapy

2004
- 2004-09-28 MX MXPA06003749A patent/MXPA06003749A/es active IP Right Grant
- 2004-09-28 SI SI200430564T patent/SI1682545T1/sl unknown
- 2004-09-28 DK DK04769496T patent/DK1682545T3/da active
- 2004-09-28 EP EP04769496A patent/EP1682545B1/en not_active Expired - Lifetime
- 2004-09-28 JP JP2006530737A patent/JP4874107B2/ja not_active Expired - Fee Related
- 2004-09-28 DE DE602004010708T patent/DE602004010708T2/de not_active Expired - Lifetime
- 2004-09-28 AT AT04769496T patent/ATE380813T1/de active
- 2004-09-28 WO PCT/IB2004/003153 patent/WO2005033107A1/en not_active Ceased
- 2004-09-28 GE GEAP20049330A patent/GEP20084417B/en unknown
- 2004-09-28 NZ NZ545837A patent/NZ545837A/en not_active IP Right Cessation
- 2004-09-28 PT PT04769496T patent/PT1682545E/pt unknown
- 2004-09-28 OA OA1200600114A patent/OA13266A/en unknown
- 2004-09-28 EA EA200600480A patent/EA009941B1/ru not_active IP Right Cessation
- 2004-09-28 CA CA2540834A patent/CA2540834C/en not_active Expired - Fee Related
- 2004-09-28 HR HR20080052T patent/HRP20080052T3/xx unknown
- 2004-09-28 AP AP2006003580A patent/AP2174A/xx active
- 2004-09-28 RS YUP-2006/0198A patent/RS20060198A/sr unknown
- 2004-09-28 US US10/953,136 patent/US7309790B2/en not_active Expired - Fee Related
- 2004-09-28 ES ES04769496T patent/ES2295924T3/es not_active Expired - Lifetime
- 2004-09-28 KR KR1020067006293A patent/KR100777885B1/ko not_active Expired - Fee Related
- 2004-09-28 BR BRPI0414862-2A patent/BRPI0414862A/pt not_active IP Right Cessation
- 2004-09-28 AU AU2004278158A patent/AU2004278158B2/en not_active Ceased
- 2004-09-28 PL PL04769496T patent/PL1682545T3/pl unknown
- 2004-09-29 HN HN2004000383A patent/HN2004000383A/es unknown
- 2004-09-29 TW TW093129475A patent/TWI280244B/zh not_active IP Right Cessation
- 2004-10-01 AR ARP040103581A patent/AR045856A1/es not_active Application Discontinuation
- 2004-10-01 PA PA20048614301A patent/PA8614301A1/es unknown
- 2004-10-01 MY MYPI20044043A patent/MY137609A/en unknown
- 2004-10-01 PE PE2004000965A patent/PE20050961A1/es not_active Application Discontinuation
- 2004-10-01 UY UY28546A patent/UY28546A1/es unknown
2006
- 2006-03-09 IL IL174208A patent/IL174208A0/en unknown
- 2006-04-03 EC EC2006006475A patent/ECSP066475A/es unknown
- 2006-04-03 MA MA28906A patent/MA28080A1/fr unknown
- 2006-05-03 NO NO20061978A patent/NO20061978L/no not_active Application Discontinuation
2007
- 2007-08-27 US US11/845,500 patent/US7790740B2/en not_active Expired - Fee Related
2008
- 2008-02-14 CY CY20081100178T patent/CY1107281T1/el unknown

Also Published As

Publication number	Publication date
MY137609A (en)	2009-02-27
UY28546A1 (es)	2005-05-31
AP2006003580A0 (en)	2006-04-30
CA2540834C (en)	2010-06-22
WO2005033107A1 (en)	2005-04-14
GEP20084417B (en)	2008-07-10
ECSP066475A (es)	2006-10-10
KR100777885B1 (ko)	2007-11-28
DK1682545T3 (da)	2008-03-17
KR20060070571A (ko)	2006-06-23
NO20061978L (no)	2006-07-03
RS20060198A (sr)	2008-09-29
US7790740B2 (en)	2010-09-07
JP4874107B2 (ja)	2012-02-15
DE602004010708T2 (de)	2008-12-04
OA13266A (en)	2007-01-31
HN2004000383A (es)	2008-10-14
IL174208A0 (en)	2006-08-01
HRP20080052T3 (hr)	2008-02-29
CY1107281T1 (el)	2012-11-21
EA200600480A1 (ru)	2006-08-25
US7309790B2 (en)	2007-12-18
PA8614301A1 (es)	2005-05-10
CA2540834A1 (en)	2005-04-14
US20050131011A1 (en)	2005-06-16
DE602004010708D1 (de)	2008-01-24
TWI280244B (en)	2007-05-01
EP1682545B1 (en)	2007-12-12
EA009941B1 (ru)	2008-04-28
AU2004278158A1 (en)	2005-04-14
AP2174A (en)	2010-11-20
AU2004278158B2 (en)	2009-08-13
NZ545837A (en)	2009-12-24
MXPA06003749A (es)	2006-06-14
MA28080A1 (fr)	2006-08-01
JP2007507483A (ja)	2007-03-29
AR045856A1 (es)	2005-11-16
TW200519112A (en)	2005-06-16
PL1682545T3 (pl)	2008-04-30
PE20050961A1 (es)	2005-11-29
BRPI0414862A (pt)	2006-11-28
EP1682545A1 (en)	2006-07-26
PT1682545E (pt)	2008-02-11
SI1682545T1 (sl)	2008-04-30
ATE380813T1 (de)	2007-12-15
US20080045563A1 (en)	2008-02-21

Publication	Publication Date	Title
US7790740B2 (en)	2010-09-07	Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
ES2263960T3 (es)	2006-12-16	Derivados de tropano como moduladores de ccr5.
JP2009533416A (ja)	2009-09-17	ケモカインｃｃｒ５受容体の調節剤としてのピロリジン誘導体
US20240374598A1 (en)	2024-11-14	Inhibitors of human immunodeficiency virus replication
US20090124635A1 (en)	2009-05-14	Chemical compounds
US7579471B2 (en)	2009-08-25	Tropane derivatives useful in therapy
JP2008525418A (ja)	2008-07-17	ケモカインｃｃｒ５受容体に対して活性を有する８−アザ−ビシクロ（３．２．１）オクタン誘導体
NL1027301C2 (nl)	2005-09-20	Tropaanderivaten.
JP2009518384A (ja)	2009-05-07	化合物
ZA200602096B (en)	2007-05-30	Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
CN1880319B (zh)	2010-06-09	作为ccr5调节剂的托烷衍生物
HK1140676A (en)	2010-10-22	Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation